SFRP4 could inhibit cancer stem-like cells (CSCs) from head and neck cancers through self-renewal, cloning and expression; moreover, CSCs with such biomarkers were more sensitive to the chemotherapeutic drug cisplatin [30]. This evidence concerns the gene SFRP4 and cancer.